표적 알파 치료의 현황 및 유용성에 대한 임상적 고찰

Clinical Review of the Current Status and Utility of Targeted Alpha Therapy

Targeted Alpha Therapy (TAT) is a new method of cancer treatment that protects normal tissues while se-lectively killing tumor cells using high cytotoxicity and short range of alpha particles, and target alpha therapy is a highly specific and effective cancer treatment strategy, and its potential has been proven through many clinical and experimental studies. This treatment method accurately delivers alpha particles by selecting specific molecules present in cancer tissue, which has an effective destruction and tumor suppression effect on cancer cells, and one of the main advantages of tar-get alpha treatment is the physical properties of alpha particles. Alpha particles have a very high energy and short effec-tive distance, interacting with target molecules in cancer tissues and having a fatal effect on cancer cells, which is known to cause DNA damage and cell death in cancer cells. TAT has shown positive results in preclinical and clinical studies for various types of cancers, especially those that resist or are unresponsive to existing treatments, but there are several challenges and limitations to overcome for successful clinical transition and application. These include the provision and production of suitable alpha radioisotopes, optimization of target vectors and delivery formulations, understanding and reg-ulation of radiological effects, accurate dosage calculation and toxicity assessment. Future research should focus on devel-oping new or improved isotopes, target vectors, transfer formulations, radiobiological models, combination strategies, imag-ing techniques, etc. for TAT. In addition, TAT has the potential to improve the quality of life and survival of cancer pa-tients due to the possibility of a new treatment for overcoming cancer, and to this end, prospective research on more carcinomas and more diverse patient groups is needed.